• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Hydroxychloroquine ineffective as post-exposure prophylaxis for Covid-19

byRayhan Saiani, MDandDeepti Shroff Karhade
June 26, 2020
in Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Hydroxychloroquine use as post-exposure prophylaxis within 4 days of a moderate or high-risk exposure did not prevent illness compatible with Covid-19 when compared to placebo.

2. Approximately 40% of individuals taking hydroxychloroquine reported side effects, all of which were noted to be mild and GI-related. There were no serious drug-related side effects observed.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The breadth of the morbidity and mortality worldwide from coronavirus disease 2019 (Covid-19) has led to an intensification of efforts to develop novel therapeutics aimed to reduce disease transmission and severity. Hydroxychloroquine has been closely studied within this context. This study employed a randomized, double blinded design to examine hydroxychloroquine use in post-exposure prophylaxis for Covid-19. Hydroxychloroquine use showed no significant reduction in the incidence of a Covid-19 illness in adults when taken within 4 days of a moderate or high-risk exposure. The study’s findings added to a growing body of literature which has yet to establish the efficacy of hydroxychloroquine within Covid-19. Limitations of this study included its reliance on a symptom driven Covid-19 identification as opposed to molecular testing and dependence on participants self-reporting all symptoms, medication adherence, and testing results. Lastly, its largely online based recruitment and survey distribution strategy likely pre-selected a healthier participant pool and may limit its generalizability. Of note, the study provided evidence for the relative safety of hydroxychloroquine. Side effects, while reported in over 40% of subjects taking the medication, were largely mild in nature and there were no reported arrythmias or deaths associated with its use. Such a finding is relevant in light of multiple recently retracted studies demonstrating potential harm associated with hydroxychloroquine use in Covid-19.

Clear here to read the study in the NEJM.

Relevant reading: Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

Use of hydroxychloroquine may be protective for cardiovascular events in patients with systemic lupus erythematosus 

In-Depth [randomized controlled trial]: The purpose of this study was to investigate if hydroxychloroquine used as postexposure prophylaxis could reduce symptomatic infections following covid-19 exposure.  Asymptomatic adults were recruited, predominantly online, based on self-reported exposure to Covid-19 within 4 days. An exposure was defined as contact with a person with confirmed Covid-19 for at least 10 minutes either without a face mask or eye shield, termed a high risk exposure, or a face mask but no eye shield, termed as a moderate risk exposure.  A total of 821 participants were enrolled, 66.4% of whom were healthcare workers. The hydroxychloroquine regimen was an initial dose of 800mg, followed by 600mg 6-8 hours later, and then 600mg daily for 4 days. The primary outcome was the development of a symptomatic illness via formal polymerase chain reaction (PCR) testing or the development of symptoms consistent with a Covid-like illness, after independent review of symptoms by four infectious disease specialists. The incidence of Covid-19 did not differ significantly between those receiving hydroxychloroquine (11.8%) or placebo (14.3%) (p =0.35) and the difference between groups was -2.4% (95% CI -7.0 to 2.2). Of participants taking hydroxychloroquine, 75.4% endorsed total compliance with the prescribed regimen and 40.1% reported a side effect at day 5, compared to 82.8% and 16.8%, respectively, in those taking the placebo.  The most common symptoms reported from those taking hydroxychloroquine were nausea, loose stools, and abdominal discomfort. There were no reported serious drug-related reactions including arrythmias or death.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Coronavirushydroxychloroquinepost-exposure prophylaxisSARS-CoV-2
Previous Post

#VisualAbstract: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Next Post

Lincocin associated with better outcomes than Azitro in treatment of COVID-19 associated pneumonia

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Cardiology

Use of hydroxychloroquine may be protective for cardiovascular events in patients with systemic lupus erythematosus 

May 19, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

November 17, 2024
Next Post
Prescription of antibiotics for acute respiratory infections increasing

Lincocin associated with better outcomes than Azitro in treatment of COVID-19 associated pneumonia

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

Identification of a genetic susceptibility locus in patients with severe Covid-19

#VisualAbstract: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic

#VisualAbstract: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Food compounds associated with disease activity in inflammatory bowel disease 
  • Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts
  • Volumetric diet and time-restricted eating demonstrate similar outcomes for weight reduction
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.